Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability, and...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab (JNJ-6372) in the treatment of patients with...

MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial...

Executive Speakers Bureau is pleased to announce the first ESB Virtual Summit on May 19-20, 2020 featuring ten elite business keynote speakers that include former executives, bestselling authors,...

INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in...